生物技术公司Revolution Medicines, Inc. (RVMD) 今日盘中股价大幅上涨5.18%，引起了市场的广泛关注。
消息面上，该公司于今日宣布对其同步进行的普通股和可转换优先票据公开发行进行定价，将融资总额大幅上调至约20亿美元。根据公告，公司将以每股142.00美元的价格发行约1056万股普通股，融资规模从此前宣布的7.5亿美元上调至约15亿美元。同时，公司还将发行总额5亿美元、2033年到期、年利率0.50%的可转换优先票据，该规模也由原计划的2.5亿美元实现翻倍。
此外，市场亦关注该公司与Tango Therapeutics在抗癌药物vopimetostat上的合作进展。双方合作的联合试验预计将于今年晚些时候公布初步数据，这为公司的研发管线增添了积极预期。此次大规模融资预计将为公司的研发支出、候选产品的潜在商业化推进以及资本支出提供充足资金，增强了投资者对其长期发展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.